Home Ingredients Lactobacillus johnsonii La1 (NCC533 / CNCM I-1225)
Gut HealthImmune Support

Lactobacillus johnsonii La1 (NCC533 / CNCM I-1225)

Lactobacillus johnsonii La1 = NCC533 = CNCM I-1225 (Nestlé strain)
Evidence Level
Moderate
3 Clinical Trials
7 Documented Benefits
3/5 Evidence Score

Specific Nestlé probiotic strain (NCC533 / CNCM I-1225 / La1) with H. pylori suppression evidence — distinguishing among Lactobacillus species via lactacin F bacteriocin production. Originally classified as Lactobacillus acidophilus group A3, later reorganized to L. johnsonii. A whey-based culture supernatant of La1 demonstrated a partial, acid-independent, long-term suppressive effect on H. pylori in humans, and frequent ingestion suppresses H. pylori colonization in asymptomatic volunteers; mouse models show attenuated H. pylori-associated gastritis and reduced proinflammatory chemokines. CNCM I-1225 is patented (Nestlé) for stomach ulcer treatment via an acidified milk product / yogurt format. The effect is suppressive, not eradicative — an adjunct to standard therapy.

Studied Dose Culture supernatant ~10^9 CFU/mL; fermented milk/yogurt ~10^10 CFU/day.
Active Compound Lactobacillus johnsonii La1 = NCC533 = CNCM I-1225 (Nestle strain); reclassified from L. acidophilus group A3.

Benefits

H. pylori suppression supernatant trial

A whey-based culture supernatant of L. johnsonii La1 demonstrated a partial, acid-independent, long-term suppressive effect on H. pylori in humans. Pivotal foundational evidence; suppressive (not eradicative) effect — an adjunct to standard therapy rather than a replacement.

Supported by Trial 1

Asymptomatic colonization suppression

Frequent ingestion of La1 in asymptomatic H. pylori-positive volunteers showed a suppressive effect on colonization. Relevant to populations where H. pylori is endemic and asymptomatic carriage is common.

Supported by Trial 2

H. pylori-associated gastritis (NCC533 fermented milk)

Fermented milk containing L. johnsonii NCC533 has a favorable effect on H. pylori-associated gastritis. Symptomatic improvement in addition to colonization suppression.

Supported by Trial 3, Trial 1

Mouse model gastritis attenuation

A mouse model showed La1 attenuates H. pylori-associated gastritis and reduces proinflammatory chemokines. Mechanistic preclinical work supporting the human gastritis findings.

Supported by Trial 3

Lactacin F bacteriocin antimicrobial

L. johnsonii produces lactacin F — a bacteriocin that forms pores in pathogen lipid bilayers, perturbing membrane permeability and potential. Distinguishing antimicrobial mechanism among Lactobacillus species — direct antimicrobial activity rather than only acid/H₂O₂ effects.

Supported by Trial 3, Trial 1

CNCM I-1225 stomach ulcer patent (Nestlé)

Nestlé patent for L. johnsonii strain CNCM I-1225 stomach ulcer treatment via acidified milk product / yogurt formulations. Industrial commitment supporting continued development; food-grade delivery via fermented dairy is the established format.

Supported by Trial 3

Suppressive vs eradicative — honest framing

Critical honest framing: La1 has suppressive (partial, long-term reduction) rather than eradicative (complete elimination) effects on H. pylori. Does not replace standard triple/quadruple H. pylori eradication therapy. Position as adjunct/complement, not substitute.

Supported by Trial 1

Mechanism of action

1

Lactacin F bacteriocin pore formation

Lactacin F forms pores in pathogen lipid bilayers, disrupting membrane permeability and potential. Distinguishing antimicrobial mechanism among Lactobacillus species.

2

Whey-based culture supernatant activity

Culture supernatant alone (without live cells) demonstrated H. pylori suppression. Postbiotic potential: secreted metabolites carry the antimicrobial activity beyond just live cell action.

3

Mucus thickness enhancement

La1 enhances gastric mucus thickness — strengthening the mucosal barrier that physically separates H. pylori from epithelial cells. Indirect mechanism reducing pathogen-host contact.

4

Adhesin competition with H. pylori

Asialo-GM1 and sulfatide adhesion receptor competition with H. pylori — La1 may occupy host cell binding sites that H. pylori would otherwise use for adhesion. Competitive exclusion at the receptor level.

5

Acid-independent suppression

The supernatant demonstrated acid-independent suppression, distinguishing it from pH-dependent mechanisms common to many Lactobacillus species. The mechanism works in the gastric environment despite H. pylori's acid tolerance.

6

Proinflammatory chemokine reduction

A mouse model showed La1 reduces proinflammatory chemokines (anti-inflammatory immunomodulation). This mechanism complements the antimicrobial activity, addressing the gastritis component of H. pylori disease.

Clinical trials

1
La1 Whey Supernatant H. pylori Suppression

Michetti P, Dorta G, Wiesel PH et al.

Clinical population described in trial publication.

Michetti P, Dorta G, Wiesel PH et al. 1999 (Digestion 60(3):203-209, doi:10.1159/000007660). Whey-based culture supernatant of L. johnsonii La1 demonstrated partial, acid-independent, long-term suppressive effect on H. pylori in humans. Foundational pivotal trial defining the suppressive (not eradicative) positioning.

2
Asymptomatic Volunteer Suppression

Frequent ingestion of La1 in asymptomatic H. pylori-positive volunteers showed suppressive effect on colonization.

Clinical population described in trial publication.

Frequent ingestion of La1 in asymptomatic H. pylori-positive volunteers showed suppressive effect on colonization. Asymptomatic population evidence.

3
PMC1317072 — La1 Mouse Model H. pylori Gastritis Attenuation

Clinical evidence on Lactobacillus johnsonii La1 (NCC533 / CNCM I-1225) for the indications and outcomes described.

Clinical population described in trial publication.

C57BL/6 mouse model. La1 attenuates H. pylori-associated gastritis and reduces proinflammatory chemokines. Mechanistic preclinical work supporting the human gastritis findings.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; food-grade probiotic origin (Nestlé fermented milk products).
Mild GI upset (rare; transient).
Pregnancy/lactation: food-grade origin supports general safety.
Long-term safety: extensive Nestlé commercial use record + multiple clinical trials.
Allergic reactions in milk-derived ingredient sensitivities (rare).
Severely immunocompromised individuals: caution (applies to all probiotics).
Industry-sponsorship (Nestlé) — important context for evidence interpretation.

Important Drug interactions

Antibiotics (eradication therapy): compatible — La1 positioned as adjunct to standard H. pylori triple/quadruple therapy.
Most medications: well-tolerated combination profile.
Immunosuppressants: caution (applies to all probiotics).
Other probiotics: compatible.
Anticoagulants: no interactions documented.
PPIs: compatible (acidified milk product format).

Featured in these supplement guides

Acid Reflux & GERD→

More Gut Health Ingredients

Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the original and most extensively clinically-studied partially hydrolyzed gua…
Gut Health
Peppermint (Mentha × piperita)
Peppermint is a hybrid mint (Mentha aquatica × Mentha spicata) whose leaves and extracted…
Gut Health
PepZinGI® (Zinc-Carnosine for Gut Lining)
PepZinGI® (NutriScience Innovations) is a unique chelate of zinc and L-carnosine in a 1:1…

Explore Other Ingredients

Antioxidant
Milk Thistle
Milk thistle, derived from the Silybum marianum plant, contains silymarin, a compound know…
Antioxidant
Alpha Lipoic Acid
Alpha-lipoic acid (ALA) is a versatile antioxidant made naturally in the body that is unus…
Antioxidant
Setria® Glutathione
Setria® is Kyowa Hakko's patented reduced L-glutathione (GSH) produced via fermentation —…

Frequently asked questions about Lactobacillus johnsonii La1 (NCC533 / CNCM I-1225)

What is Lactobacillus johnsonii La1 used for?

L. johnsonii La1 (also called La1 or NCC533) is studied for gut and immune support, including research on modulating Helicobacter pylori colonization and supporting the stomach and gut lining.

How much L. johnsonii La1 should I take?

It is dosed in the billions of CFU per day, often delivered in fermented dairy or capsules; follow the specific product's labeling. Strain identity is key, so confirm it is the La1 strain.

When should I take L. johnsonii La1?

Once daily, with or before a meal. For gut and stomach-related goals, consistent use over several weeks is the studied approach.

Is L. johnsonii La1 safe?

It is generally very safe and well tolerated. Severely immunocompromised or critically ill people should check with a doctor before taking live probiotics.

What is Lactobacillus johnsonii La1?

Specific Nestlé probiotic strain (NCC533 / CNCM I-1225 / La1) with H. pylori suppression evidence — distinguishing among Lactobacillus species via lactacin F bacteriocin production. Originally classified as Lactobacillus acidophilus group A3, later reorganized to L. johnsonii.

What is the recommended dosage of Lactobacillus johnsonii La1?

The clinically studied dose is Culture supernatant ~10^9 CFU/mL; fermented milk/yogurt ~10^10 CFU/day. Always follow the product label and check with a healthcare provider for personal advice.

Is Lactobacillus johnsonii La1 safe, and does it have side effects?

For most healthy adults, Lactobacillus johnsonii La1 is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; food-grade probiotic origin (Nestlé fermented milk products). Mild GI upset (rare; transient). It may also interact with some medications. Lactobacillus johnsonii La1 is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Lactobacillus johnsonii La1 interact with any medications?

Possible interactions include: Antibiotics (eradication therapy): compatible — La1 positioned as adjunct to standard H. pylori triple/quadruple therapy. Most medications: well-tolerated combination profile. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Lactobacillus johnsonii La1?

NutraSmarts rates the evidence for Lactobacillus johnsonii La1 as Moderate (3 out of 5). It is backed by 3 clinical trials and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Gotteland M, Andrews M, Toledo M, et al. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children. Nutrition. 2008;24(5):421-6..PubMedUsed to support: Randomized trial of Lactobacillus johnsonii La1 modulating Helicobacter pylori colonization in children.